Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/IDH2_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/IDH2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/IDH2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/IDH2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/IDH2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/IDH2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/IDH2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/IDH2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/IDH2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:200014611 | Breast | DCIS | negative regulation of cell motility | 46/1390 | 359/18723 | 2.01e-04 | 3.23e-03 | 46 |
GO:00420632 | Breast | DCIS | gliogenesis | 39/1390 | 301/18723 | 4.76e-04 | 6.25e-03 | 39 |
GO:003033611 | Breast | DCIS | negative regulation of cell migration | 43/1390 | 344/18723 | 5.41e-04 | 6.96e-03 | 43 |
GO:004001311 | Breast | DCIS | negative regulation of locomotion | 47/1390 | 391/18723 | 7.30e-04 | 8.69e-03 | 47 |
GO:005070822 | Breast | DCIS | regulation of protein secretion | 35/1390 | 268/18723 | 7.83e-04 | 9.11e-03 | 35 |
GO:00602531 | Breast | DCIS | negative regulation of glial cell proliferation | 5/1390 | 15/18723 | 3.58e-03 | 2.92e-02 | 5 |
GO:007169222 | Breast | DCIS | protein localization to extracellular region | 41/1390 | 368/18723 | 6.01e-03 | 4.29e-02 | 41 |
GO:000930622 | Breast | DCIS | protein secretion | 40/1390 | 359/18723 | 6.59e-03 | 4.61e-02 | 40 |
GO:003559222 | Breast | DCIS | establishment of protein localization to extracellular region | 40/1390 | 360/18723 | 6.90e-03 | 4.77e-02 | 40 |
GO:0006091 | Colorectum | AD | generation of precursor metabolites and energy | 209/3918 | 490/18723 | 3.17e-28 | 6.61e-25 | 209 |
GO:0009060 | Colorectum | AD | aerobic respiration | 108/3918 | 189/18723 | 9.14e-28 | 1.43e-24 | 108 |
GO:0045333 | Colorectum | AD | cellular respiration | 119/3918 | 230/18723 | 3.21e-25 | 4.02e-22 | 119 |
GO:0015980 | Colorectum | AD | energy derivation by oxidation of organic compounds | 143/3918 | 318/18723 | 2.78e-22 | 2.49e-19 | 143 |
GO:0009117 | Colorectum | AD | nucleotide metabolic process | 168/3918 | 489/18723 | 2.20e-12 | 3.36e-10 | 168 |
GO:0006753 | Colorectum | AD | nucleoside phosphate metabolic process | 169/3918 | 497/18723 | 4.99e-12 | 6.98e-10 | 169 |
GO:0006099 | Colorectum | AD | tricarboxylic acid cycle | 19/3918 | 30/18723 | 5.82e-07 | 2.09e-05 | 19 |
GO:0006066 | Colorectum | AD | alcohol metabolic process | 106/3918 | 353/18723 | 3.02e-05 | 5.57e-04 | 106 |
GO:0044262 | Colorectum | AD | cellular carbohydrate metabolic process | 87/3918 | 283/18723 | 6.00e-05 | 1.01e-03 | 87 |
GO:1901293 | Colorectum | AD | nucleoside phosphate biosynthetic process | 80/3918 | 256/18723 | 6.31e-05 | 1.05e-03 | 80 |
GO:0050708 | Colorectum | AD | regulation of protein secretion | 83/3918 | 268/18723 | 6.59e-05 | 1.07e-03 | 83 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IDH2 | SNV | Missense_Mutation | rs770548230 | c.1054N>C | p.Thr352Pro | p.T352P | P48735 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.985) | TCGA-B6-A40B-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IDH2 | SNV | Missense_Mutation | rs770548230 | c.1054N>C | p.Thr352Pro | p.T352P | P48735 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.985) | TCGA-EW-A423-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
IDH2 | deletion | Frame_Shift_Del | novel | c.1182delN | p.Phe394LeufsTer18 | p.F394Lfs*18 | P48735 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
IDH2 | SNV | Missense_Mutation | rs781481805 | c.1247N>T | p.Ala416Val | p.A416V | P48735 | protein_coding | deleterious_low_confidence(0.01) | benign(0.43) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
IDH2 | SNV | Missense_Mutation | rs267606870 | c.418C>T | p.Arg140Trp | p.R140W | P48735 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
IDH2 | SNV | Missense_Mutation | | c.1322N>C | p.Ile441Thr | p.I441T | P48735 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.948) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
IDH2 | SNV | Missense_Mutation | rs201173543 | c.140N>T | p.Ala47Val | p.A47V | P48735 | protein_coding | tolerated_low_confidence(0.13) | benign(0.012) | TCGA-AA-3833-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IDH2 | SNV | Missense_Mutation | rs781481805 | c.1247N>T | p.Ala416Val | p.A416V | P48735 | protein_coding | deleterious_low_confidence(0.01) | benign(0.43) | TCGA-AA-A01Z-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
IDH2 | SNV | Missense_Mutation | | c.992N>T | p.Thr331Met | p.T331M | P48735 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.998) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IDH2 | SNV | Missense_Mutation | | c.560N>T | p.Asp187Val | p.D187V | P48735 | protein_coding | deleterious_low_confidence(0.01) | benign(0.117) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3418 | IDH2 | CLINICALLY ACTIONABLE, ENZYME | | AG-881 | | |
3418 | IDH2 | CLINICALLY ACTIONABLE, ENZYME | | AGI-6780 | | 23558173 |
3418 | IDH2 | CLINICALLY ACTIONABLE, ENZYME | | enasidenib | ENASIDENIB | |
3418 | IDH2 | CLINICALLY ACTIONABLE, ENZYME | | Enasidenib | ENASIDENIB | |
3418 | IDH2 | CLINICALLY ACTIONABLE, ENZYME | | VENETOCLAX | VENETOCLAX | 30725494 |
3418 | IDH2 | CLINICALLY ACTIONABLE, ENZYME | | Enasidenib | ENASIDENIB | 28588020,28193778 |
3418 | IDH2 | CLINICALLY ACTIONABLE, ENZYME | | ENASIDENIB | ENASIDENIB | 28588020,28193778 |
3418 | IDH2 | CLINICALLY ACTIONABLE, ENZYME | inhibitor | 404859110 | | |
3418 | IDH2 | CLINICALLY ACTIONABLE, ENZYME | | Venetoclax | VENETOCLAX | 27520294 |
3418 | IDH2 | CLINICALLY ACTIONABLE, ENZYME | | Venetoclax | VENETOCLAX | |